Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review

Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Zheng, Yao, Zhi-Hua, Yao, Shu-Na, Xia, Qing-Xin, Wang, Hai-Ying, Chu, Jun-Feng, Song, Ming, Zhao, Shuang, Liu, Yan-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394502/
https://www.ncbi.nlm.nih.gov/pubmed/32801876
http://dx.doi.org/10.2147/CMAR.S254007
Descripción
Sumario:Primary mediastinal large B-cell lymphoma (PMBCL) is relatively infrequent and generally has a good prognosis with standard immunochemotherapy. However, treatment options are limited for patients with relapsed/refractory PMBCL who are ineligible for stem cell transplantation. In this report, we treated a refractory PMBCL patient, who did not respond to salvage chemotherapy, with combined nivolumab and radiotherapy. The patient achieved a complete remission with mild adverse reactions and has survived without relapse 2 years after treatment.

Ejemplares similares